Improved Quality of Life Among Chronic Pancreatitis Patients Undergoing Total Pancreatectomy With Islet Autotransplantation-Single Center Experience With Large Cohort of Patients.

Autor:	Coluzzi M; Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States.; Unit of General and Emergency Surgery, Azienda Ospedaliera Regionale San Carlo, Potenza, Italy., Takita M; Department of Radiation Health Management, Fukushima Medical University, Fukushima, Japan., Saracino G; Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States., Rub Hakim Mohammed A; Baylor Scott and White Research Institute, Dallas, TX, United States., Darden CM; Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States., Testa G; Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States., Beecherl E; Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States., Onaca N; LifeGift, Fort Worth, TX, United States., Naziruddin B; Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, United States.
Jazyk:	angličtina
Zdroj:	Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2023 Sep 04; Vol. 36, pp. 11409. Date of Electronic Publication: 2023 Sep 04 (Print Publication: 2023).
DOI:	10.3389/ti.2023.11409
Abstrakt:	Total pancreatectomy with islet autotransplantation (TPIAT) is the treatment of choice to preserve pancreatic endocrine function, alleviate pain, and improve quality of life (QoL) when other strategies are ineffective for chronic pancreatitis (CP) patients. This study utilized pancreatic disease-specific surveys developed by the European Organisation for Research and Treatment of Cancer (EORTC) to conduct a comprehensive, single-center examination of a large cohort of patients to gain understanding of QoL post-TPIAT. Two validated QoL surveys of the EORTC-QLQ-C30 and QLQ-PAN26-were administered in a prospective cohort of CP patients during pre-and post-operative scheduled visits. A total of 116 patients responded to the preoperative survey and were included in this study. The global health scale of QLQ-C30 was significantly improved after TPIAT when compared to baseline with delta scores of 24.26, 20.54, and 26.7 at 1, 2, and 3 years post-TPIAT ( p < 0.001). The EORTC-PAN26 revealed significant improvements in symptom scales for pancreatic pain, bloating, digestive symptoms, taste, indigestion, weight loss, body image, and future worries. The comprehensive surveys in such a large cohort expands the QoL criterion in CP patients and indicates significant improvement in QoL post-TPIAT, further validating TPIAT as a treatment option for refractory CP. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Coluzzi, Takita, Saracino, Rub Hakim Mohammed, Darden, Testa, Beecherl, Onaca and Naziruddin.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu